Valsacor HD 160 tablets film-coated

Valsts: Armēnija

Valoda: angļu

Klimata pārmaiņas: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktīvā sastāvdaļa:

valsartan, hydrochlorothiazide

Pieejams no:

KRKA d.d.

ATĶ kods:

C09DA03

SNN (starptautisko nepatentēto nosaukumu):

valsartan, hydrochlorothiazide

Deva:

160mg+ 25mg

Zāļu forma:

tablets film-coated

Vienības iepakojumā:

(14/1x14/) in blister, (28/2x14/) in blister

Receptes veids:

Prescription

Autorizācija statuss:

Registered

Autorizācija datums:

2016-06-08

Produkta apraksts

1.3.1
Valsartan + Hydrochlorothiazide
SPC, Labeling and Package Leaflet
AM
SmPCPIL158312_1
21.10.2020 – Updated: 21.10.2020
Page 1 of 18
1.
NAME OF THE MEDICINAL PRODUCT
Valsacor
®
HD 160 160 mg/25 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 160 mg valsartan and 25 mg
hydrochlorothiazide.
Excipient with known effect:
-
lactose monohydrate (34.25 mg), which is equivalent to 32.54 mg
lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light brown, oval, biconvex, film coated tablets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension in adults.
Valsacor HD 160 fixed-dose combination is indicated in patients whose
blood pressure is not
adequately controlled on valsartan or hydrochlorothiazide monotherapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology_
The recommended dose of Valsacor HD 160 160 mg/25 mg is one film
coated tablet once daily. Dose
titration with the individual components is recommended. In each case,
up-titration of individual
components to the next dose should be followed in order to reduce the
risk of hypotension and other
adverse events.
When clinically appropriate, a direct change from monotherapy to the
fixed combination may be
considered in patients whose blood pressure is not adequately
controlled on valsartan or
hydrochlorothiazide monotherapy, provided the recommended dose
titration sequence for the
individual components is followed.
The clinical response to Valsacor HD 160 should be evaluated after
initiating therapy and if blood
pressure remains uncontrolled, the dose may be increased by increasing
either one of the components
to a maximum dose of valsartan/hydrochlorothiazide 160 320 mg/25 mg.
The antihypertensive effect is substantially present within 2 weeks.
In most patients, maximal effects are observed within 4 weeks.
However, in some patients, 4–8 weeks
of treatment may be required. This should be taken into account during
dose titr